{"prompt": "['Alliance A221504', 'strategies to ameliorate MOR-associated disease progression. Due to increased stress and', 'pain, circulating levels of beta-endorphin and SP will be higher in subjects with higher', 'disease burden, progression and pain. These will be even higher in subjects on higher doses', 'of opioids, but may be attenuated in those receiving naloxegol that blocks peripheral opioid', 'receptors. In this pilot study, statistical analysis of these correlative studies will be', 'exploratory and hypothesis-generating.', 'Potential for future clinical translation:', 'Importantly, these correlative studies performed in a clinical setting will identify the', 'receptors and signaling pathways activated in association with MOR. This would lead to', 'future investigations to determine mechanisms underlying MOR-induced co-activation of', 'these specific signaling pathways in human endothelial and/or cancer cells. In turn, these', 'observations will provide targets to block MOR-induced tumor progression without', 'compromising analgesia. Additionally, if we observe an inhibitory effect of naloxegol on', 'mitogenic signaling pathways in the tumor, it could be further examined for its effect in', 'combination with standard systemic anti-cancer therapies to improve clinical outcomes', 'including HRQoL.', '15.0 GENERAL REGULATORY CONSIDERATIONS AND CREDENTIALING', 'None', '56', 'Update 2', 'Version Date 6/25/2019']['Alliance A221504', '16.0 REFERENCES', '1. Gupta K, Kshirsagar S, Chang L, et al. Morphine stimulates angiogenesis by activating proangiogenic', 'and urvival-promoting signaling and promotes breast tumor growth. Cancer Res. 2002;62(15):4491-', '4498.', '2. Fujioka N, Nguyen J, Chen C, et al. Morphine-induced epidermal growth factor pathway activation in', 'non-small cell lung cancer. Anesth Analg. 2011;113(6):1353-1364', '3. Madar I, Bencherif B, Lever J, et al. Imaging delta- and mu-opioid receptors by PET in lung carcinoma', 'patients. J Nucl Med. 2007;48(2):207-213', '4.', 'Mathew B, Lennon FE, Siegler J, et al. The novel role of the mu opioid receptor in lung cancer', 'progression: a laboratory investigation. Anesth Analg. 2011;112(3):558-567.', '5. Zylla D, Gourley BL, Vang D, et al. Opioid requirement, opioid receptor expression, and clinical', 'outcomes in patients with advanced prostate cancer. Cancer. 2013;119(23):4103-4110.', '6.', 'WHO. Globocan 2012: Estimated cancer incidence, mortality and prevalence worldwide in 2012. Vol.', '2014; 2012.', '7. Siegel RL, Miller KD, Jema A. Cancer Statistics 2016. CA Cancer J Clin. 2016;66:7-30', '8. van den Beuken-van Everdingen MH, de Rijke JM, Kessels AG, Schouten HC, van Kleef M, Patijn J.', 'Prevalence of pain in patients with cancer: a systematic review of the past 40 years. Ann Oncol.', '2007;18(9):1437-1449.', '9. Scagliotti GV, Gridelli C, de Marinis F, et al. Efficacy and safety of maintenance pemetrexed in patients', 'with advanced nonsquamous non-small cell lung cancer following pemetrexed plus cisplatin induction', 'treatment: A cross-trial comparison of two phase III trials. Lung Cancer. 2014;85(3):408-414.', '10. Belani CP, Brodowicz T, Ciuleanu TE, et al. Quality of life in patients with advanced non-small-cell', 'lung cancer given maintenance treatment with pemetrexed versus placebo (H3E-MC-JMEN): results', 'from a randomised, double-blind, phase 3 study. Lancet Oncol. 2012;13(3):292-299.', '11. Cella D, Eton DT, Fairclough DL, et al. What is a clinically meaningful change on the Functional', 'Assessment of Cancer Therapy-Lung (FACT-L) Questionnaire? Results from Eastern Cooperative', 'Oncology Group (ECOG) Study 5592. J Clin Epidemiol. 2002;55(3):285-295.', '12. Cullen MH, Billingham LJ, Woodroffe CM, et al. Mitomycin, ifosfamide, and cisplatin in unresectable', 'non-small-cell lung cancer: effects on survival and quality of life. J Clin Oncol. 1999;17(10):3188-', '3194.', '13. Singleton PA, Mirzapoiazova T, Salgia R, Moss J. Morphine increases multidrug resistance in human', 'lung cancer through regulation of ABCC3 in caveolin-enriched microdomains. Am J Respir Crit Care', 'Med. 2015;191:A2424.', '14. Singleton PA, Moss J, Karp DD, Atkins JT, Janku F. The mu opioid receptor: A new target for cancer', 'therapy? Cancer. 2015;121(16):2681-2688.', '15. Temel JS, Greer JA, Muzikansky A, et al. Early palliative care for patients with metastatic non-small-', 'cell lung cancer. N Engl J Med. 2010;363(8):733-742.', '16. Diego L, Atayee R, Helmons P, Hsiao G, von Gunten CF. Novel opioid antagonists for opioid-induced', 'bowel dysfunction. Expert Opin Investig Drugs. 2011;20(8):1047-1056', '17. Scagliotti GV, Parikh P, von Pawel J, et al. Phase III study comparing cisplatin plus gemcitabine with', 'cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung', 'cancer. J Clin Oncol. 2008;26(21):3543-3551.', '57', 'Update 2', 'Version Date 6/25/2019']\n\n###\n\n", "completion": "END"}